Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Companies

St George's, University of London

St George's University of London (SGUL) is a dual faculty institution, offering medicine and health sciences.

The company in detail

Profile

St George’s University of London (SGUL) is a dual faculty institution, offering medicine and health sciences. Our mission is to promote — by excellence in teaching, clinical practice and research — the prevention, treatment and understanding of disease. The institution is extremely active in research and has an especially high reputation in diseases of the heart and circulation, and in the science and clinical practice associated with problems of infection and immunity. Research is also strong in basic medical sciences, particularly cell biology and molecular genetics. Other influential fields include medical epidemiology and public health. Our research greatly benefits from SGUL being embedded within one of the busiest hospitals in the UK, St George’s Healthcare Trust, providing a huge patient catchment area and clinical trials activity.

Partnering strategy/interests

Out-licensing

A test that has shown the ability to diagnose pre-eclampsia from first trimester serum samples with 67% sensitivity More
A biomarker combination that has shown a high degree of sensitivity and accuracy More
A series of reagents that promise potential for early diagnosis of Alzheimer's Disease using MRI More
Small peptide that has shown encoraging anticancer activity in vitro and in vivo More
The technology consists of markers whose expression discriminates between patients with prostate cancer and patients without at a rate of 95% correct diagnosis, and between localised and metastatic prostate cancer with a correct diagnosis of 85%. More

Deals

To view this information, you must subscribe to Partneringtools.

Head office

St George's, University of London
Cranmer Terrace
London
SW17 0RE
United Kingdom

Tel:  +44 208 266 6865
Fax: +44 208 266 6867
www | email

Contact details

Aleksandra Wright
Technology Transfer Officer
Request more information
Dr Sharon Spencer
Director of Enterprise
Request more information

Related categories

Partnering consultation free of charge
Genesis
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us